Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-Guard in early diffuse cutaneous systemic sclerosis
NL-OMON60269Phase 2Recruiting
- Sponsor
- Philikos BV
- Start
- Apr 2025
- Modality
- Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of T-Guard in diffuse cutaneous systemic sclerosis (dcSSc) (2 arms), sponsored by Philikos BV. Primary endpoint: Incidence of Grade 3 or higher adverse events. Started Apr 2025; status: recruiting.
02
Drugs
T-Guard
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NL-OMON60269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60269.